by David Wallace A disease modifying drug for MPN patients specifically targets disease-initiating stem cells that lead to MPN phenotypes, leading to regression of the disease while improving associated complications. Our guest MPN expert is Dr. Ghaith Abu-Zeinah from Weill Cornell Medicine in NYC. Listen in to learn more.